QUALITY OF LIFE AND FECAL CALPROTECTIN IN INFLAMMATORY BOWEL DISEASES

  • Otilia GAVRILESCU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Mihaela DRANGA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Camelia SOPONARU University “Alexandru Ioan Cuza” Iasi
  • Liliana Nicoleta MIHALCEA University “Alexandru Ioan Cuza” Iasi
  • Cristina CIJEVSCHI PRELIPCEANU “Sf. Spiridon” County Clinical Emergency Hospital Iasi
  • Catalina MIHAI “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

Inflammatory diseases (IBD) are chronic disorders marked by periods of activity that require repeated in-hospital care, expensive surgical treatment with multiple side effects which affect the quality of life in these patients. Mucosal healing is associated with sustainable remission and a low risk of surgical intervention in these patients. Aim: To evaluate the correlations between fecal calprotectin (used as a marker of endoscopic inflammation) and quality of life (assessed by means of the IBDQ-32 questionnaire). Material and methods: A prospective study that includes 60 patients with IBD. Fecal calprotectin and Inflammatory bowel disease questionnaire-32 were performed in all patient. Results: The average value of fecal calprotectin was 247.38±345.77µg/g. The average total IBDQ was 137.42±38. There are negative statistical correlations between the activity of the disease assessed by means of the UCDAI and CDAI scores in the two studied disorders and the quality of life assessed by means of the IBDQ-32 score. We noticed significant correlations between the values of fecal calprotectin and the quality of life. Conclusions: The activity of the disease had a negative impact on the quality of life in the patients with IBD. Clinical manifestations are more likely to affect quality of life compared to the endoscopic activity of the disease.

Author Biographies

Otilia GAVRILESCU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi
Department of Gastroenterology and Hepatology

Mihaela DRANGA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi
Department of Gastroenterology and Hepatology

Cristina CIJEVSCHI PRELIPCEANU, “Sf. Spiridon” County Clinical Emergency Hospital Iasi

Department of Gastroenterology and Hepatology

Catalina MIHAI, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (I)
“Sf. Spiridon” County Clinical Emergency Hospital Iasi
Department of Gastroenterology and Hepatology

References

1. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012; 61: 1619-1635.
2. Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol 2015; 50: 74-80.
3. D’Haens G, Ferrante M, Vermeire S et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2218-2224.
4. Sipponen T, Bjorkesten CG, Farkkila M et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment. Scand J Gastroenterol 2010; 45: 325-331.
5. MagroF, GionchettiP, EliakimR et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. JCC 2017; 11(6): 649-670.
6. GomollónF, DignassA, Annese V et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. JCC 2017; 11(1): 3-25.
7. Macovei L, Presura R, Anghel L et al. Coronary stent entrapment. Postep Kardiol Inter 2014; 10(37): 216-218.
8. Pacolet J, Deliège D, Artoisenet C et al. Vieillissement, aide et soins de santé en Belgique. Rapport pour le SPF securité sociale direction Générale politique sociale 2004: 143-165.
9. Bjordal K. Impact of quality of life measurement in daily clinical practice. Ann Oncol 2004; 15(4): 279-282.
10. Carr AJ, Gibson BA, Robinson PG. Is quality of life determined by expectations or experience? BMJ 2001; 322: 1240-1243.
11. Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clin Epidemiol 2013; 5: 237-247.
12. Rubin GP, Hungin APS, Chinn DJ, Dwarakanath D. Quality of life in patients with established in-flammatory bowel disease: a UK general practice survey. Aliment Pharmacol Ther 2004; 19: 529-535.
13. Kalafateli M, Triantos C, Theocharis G et al. Health-related quality of life in patients with inflammatory bowel disease: a single-center experience. Ann Gastroenterol 2013; 26 (2): 1-6.
14. Garud S, Peppercorn MA. Ulcerative colitis: current treatment strategies and future prospects. Therap Adv in Gastroenterol 2009; 2(2): 99-108.
15. Van Rheenen PF, Van de Vijver E, FidlerV. Fecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 342: c3369.
16. von Roon AC, Karamountzos L, Purkayastha S et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancies. Am J Gastroenterol 2007; 102: 803-813.
17. Nedelciuc O, Pintilie I, Dranga M et al. Quality of life in patients with ulcerative colitis. Rev Med Chir Soc Med Nat Iasi 2012; 116(3): 756-760.
18. Gavrilescu O, Dranga M, Mihai C, Prelipcean CC. Quality of life in Crohn's disease patients. Rev Med Chir Soc Med Nat Iasi 2015; 119(2): 340-345.
Published
2018-06-29
Section
INTERNAL MEDICINE - PEDIATRICS